Cyient DLM Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lkx0iw0ocqd52l9u21j8rxok.pdf

Key Takeaways


Revenue & Profitability

Anthony Montalbano: "I think you'll find that EBITDA margins, 9%-10% is relatively healthy in the Indian EMS sector. And then, it's definitely extremely healthy on the global sector as well where, EBITDA margins are anywhere from 3%, 4%, 5%, sometimes 6%."

Order Book & Demand Environment

Anthony Montalbano: "We did announce a new logo, a new client in an industrial sector last quarter. And this sector actually moves extremely fast with the segment this client is in. So, we see that just the revenue potential from this new logo alone for our next fiscal year to be quite considerable to the fact where it would probably be a top three or four clients for us alone in the next fiscal year."

Working Capital & Balance Sheet


Altek Electronics Acquisition

Anthony Montalbano: "For us, the value proposition needs to include having a similar type of DNA in the business where our clients who do business with us today in India would feel very confident having their type of business being supported in a similar type of operation in other geographies."

Revenue Mix & Segments


Strategy & Growth Levers

Krishna Bodanapu: "I think there is a synergy because the continuum is really first you build it - first you design, then you build the chip and then you build the board and the box and everything around it. So, in that sense there is a continuum, I will say and therefore there is a synergy, but I think we won't expect anything to play out from that synergy at least for a few years because we will first have to start designing the chips and then looking at how those chips can be consumed in science DLM."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year EBITDA marginFlat YoY, comparable with FY24; H2 will be better than H1FY25
Double-digit EBITDA margin"We will definitely end the year with double-digit"FY25 exit
PAT trajectoryImproved trajectory in H2 as revenue and EBITDA peakH2 FY25
DIO target90-100 days on a sustainable basisNo fixed date (action plan in place)
Working capitalContinued improvement in coming quartersComing quarters
IPO proceedsFully utilized (inorganic + general corporate purposes)Next quarter (Q3 FY25)
Industrial order book recoveryRecovery expected as client inventory is consumed1-2 more quarters
30% organic CAGRStill the target; does not include inorganicMultiyear
Altek integration into reportingIntegrated into overall updatesStarting next quarter (Q3 FY25)
One-time transaction costsAll taken in Q3 and called out separatelyQ3 FY25

Key Metrics

MetricQ2 FY25
Revenue₹389.4 cr, +33.4% YoY
EBITDA₹31.6 cr, +34.4% YoY
EBITDA margin8.1%, flattish YoY
PAT₹15.5 cr, +5.5% YoY
PAT margin4%, lower YoY due to higher finance costs
H1 FY25 revenue growth27.2% YoY
H1 FY25 EBITDA growth18.6% YoY
H1 FY25 PAT growth31% YoY
FY25 EBITDA margin outlookflat YoY (FY24 full-year EBITDA was 9.2%); H1 FY25 EBITDA margin was 8.5%
Order backlog₹1,979 cr, down ₹147.7 cr QoQ
Order backlog mix60% export, 40% domestic
DIO122 days, improved from 184 days in Q1
DSO82 days, improved from 92 days in Q1
Customer advances20 days, decline due to change in business mix
New logos added2, a defense contract in India and a global oil services company
Altek acquisition upfront payment$23.4 mn; earn-out capped at $5.85 mn; total max payout $29.2 mn
Altek financial profiledouble-digit EBITDA, ROC >15%, EPS-accretive from FY26
Altek industry mix>95% industrial and medical
Short-term borrowings₹225 cr, up from ₹58 cr; borrowing for acquisition ~$12 mn (~₹100 cr)